Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center

Paweł Kralisz; Marek Frank; Bożena Sobkowicz; Slawomir Dobrzycki; Tomasz Hirnle

doi:10.5114/aic.2021.104776

eISSN: 1897-4295
ISSN: 1734-9338

Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2021
vol. 17

Send email

Copy url:

abstract:

Short communication

Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center

Paweł Kralisz

¹

,

Marek Frank

²

,

Bożena Sobkowicz

³

,

Slawomir Dobrzycki

¹

,

Tomasz Hirnle

²

Department of Invasive Cardiology, University Hospital, Bialystok, Poland
Department of Cardiosurgery, University Hospital, Bialystok, Poland
Department of Cardiology, University Hospital, Bialystok, Poland

Adv Interv Cardiol 2021; 17, 1 (63): 105–108

DOI: https://doi.org/10.5114/aic.2021.104776

Online publish date: 2021/03/27

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Kralisz P, Frank M, Sobkowicz B, Dobrzycki S, Hirnle T. Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2021;17(1):105-108. doi:10.5114/aic.2021.104776.

APA

Kralisz, P., Frank, M., Sobkowicz, B., Dobrzycki, S.,  & Hirnle, T. (2021). Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 17(1), 105-108. https://doi.org/10.5114/aic.2021.104776

Chicago

Kralisz, Paweł, Marek Frank, Bożena Sobkowicz, Slawomir Dobrzycki,  and Tomasz Hirnle. 2021. "Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej 17 (1): 105-108. doi:10.5114/aic.2021.104776.

Harvard

Kralisz, P., Frank, M., Sobkowicz, B., Dobrzycki, S.,  and Hirnle, T. (2021). Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 17(1), pp.105-108. https://doi.org/10.5114/aic.2021.104776

MLA

Kralisz, Paweł et al. "Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, vol. 17, no. 1, 2021, pp. 105-108. doi:10.5114/aic.2021.104776.

Vancouver

Kralisz P, Frank M, Sobkowicz B, Dobrzycki S, Hirnle T. Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2021;17(1):105-108. doi:10.5114/aic.2021.104776.

In recent years, there has been a clear trend towards increased mitral bioprosthetic valve surgery in comparison to mechanical prostheses [1]. According to the ESC Guidelines mitral bioprostheses are recommended for patients > 70 years old or those with a life expectancy lower than the presumed durability of the bioprosthesis (class IIa/C). Importantly, the guidelines also recognize the prominence of quality of life after cardiosurgery and focus on patients’ preferences (class Ic), especially if long-term anticoagulation is nonoptimal (class Ic) [2]. Structural deterioration of mitral bioprostheses (structural valve deterioration – SVD) is the main limitation for their use. The average lifespan of a bioprosthetic valve is estimated at 16 years and the reoperation due to SVD affects as many as 75% of patients after a 20-year follow-up [3, 4]. Reoperation is usually associated with high risk of complications and mortality [5, 6].

Transcatheter transseptal mitral valve implantation with Edwards SAPIEN 3: the first experience of a single center

Paweł Kralisz 1 , Marek Frank 2 , Bożena Sobkowicz 3 , Slawomir Dobrzycki 1 , Tomasz Hirnle 2

Paweł Kralisz

¹

,

Marek Frank

²

,

Bożena Sobkowicz

³

,

Slawomir Dobrzycki

¹

,

Tomasz Hirnle

²